Science1 publisher3 min readPublished
Inflammation in lupus-prone mice dulls the neutrophil sensor for bacterial lactate
In lupus-prone mice, inflammatory signals lowered the protein neutrophils use to sense bacterial lactate and pushed them toward a faster, weaker trap. Standard lupus drugs cut bacterial counts in organs but not deaths.
The Scientist · Science desk
What happened
- Healthy neutrophils meeting Staphylococcus aureus sense the lactate the bacteria make, a cue that triggers a DNA-and-protein trap rich in antibacterial proteins and kills the neutrophil that builds it.
- In mice with lupus, inflammatory molecules reduced levels of the protein neutrophils need to sense that bacterial lactate, interfering with the antibacterial response.
- A second inflammatory molecule pushed the cells toward a different trap they could release faster, which spared the neutrophil and killed bacteria less effectively.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- constraint Fewer bacteria in organs without a survival benefit limits what the drug arm can support: clearing an organ is not the endpoint that decides whether an infected animal, or a patient, lives.
- contradiction Earlier work finding that blocking NET formation does not necessarily improve lupus cuts against trap quantity as the driver, and this result offers trap type as the variable to test instead.
- capability Clinicians now have a specific, measurable candidate to explain why infection risk differs between patients on similar regimens, namely which trap the neutrophil builds when bacteria arrive.
- decision Nobody can change a prescription on this: the work supports correcting a neutrophil defect in mice, and the infection-rate question in people is untested.
A neutrophil has more than one way to build a trap, and the two described here differ in what they cost the cell. Lactate from Staphylococcus aureus triggers a trap loaded with antibacterial proteins, and making it kills the neutrophil that made it [2]. The form favoured by inflammation in lupus comes out faster, spares the cell, and kills bacteria less well [4]. Two inflammatory signals push in the same direction: one lowers the lactate sensor, the other promotes the quick trap [3][4].
The cue makes the design informative. Lactate is a bacterial byproduct, so a lower sensor removes an infection-specific signal while the inflammation-driven route to trap-making stays open [2][3][4].
Treated lupus-prone mice carried fewer bacteria in several organs, and survival did not significantly improve over untreated animals [5]. Bacterial burden is a surrogate. It reports whether a drug restored part of a pathway; survival turns on more than that, and the brief lists other immune cells, tissue damage and further features of lupus as likely contributors to poor outcomes during infection [14].
The account is explicit that some infection risk in lupus comes from immunosuppressive medication, and that the disease itself also alters how immune cells function [6]. So this sits alongside the drug explanation. What it adds is a specific defect in a specific first-responder cell, in mice [3].
Within lupus research the role of these traps is unsettled. Some studies have found that disrupting the pathways NET formation requires does not necessarily improve lupus [7]. This work suggests the kind of trap and the circumstances of its release matter more than the count [8], and that during infection lupus neutrophils may make a trap that kills bacteria poorly while still releasing inflammatory material [13].
Writing in The Conversation, the researcher who led the work put the finding this way: "The result is not an immune system that is weak, but an immune response that is highly active but misdirected." [10] The same brief states that the results do not show that people taking standard lupus treatments will have fewer infections, only that existing therapies can correct immune defects that may contribute to susceptibility [9]. The brief gives no bacterial counts, survival figures or group sizes, and it does not name the drugs tested or the protein that senses lactate [15].
This does not tell you whether human neutrophils behave the same way, and in my view the claim stays a mouse mechanism until someone shows the lowered sensor in cells from patients. It is a testable explanation for something clinicians already see, which is that infection risk, disease activity and treatment response vary between people with lupus in ways drug dose alone does not account for [16]. The team says its next work is to define how different NETs are generated, what they contain, and whether particular kinds are protective or harmful in different contexts [11].
What to watch
- The underlying paper, and whether it names the lactate-sensing protein and the drugs tested, with bacterial counts and group sizes.
- Whether the lowered sensor shows up in neutrophils taken from people with lupus, and with bacteria other than Staphylococcus aureus.
- Whether NET-directed drug programmes begin specifying which NET pathway they hit, given earlier results where blocking formation did not improve lupus.